Children with acute lymphoblastic leukemia can benefit from K2 and D3 supplementation
Acute lymphoblastic leukemia (ALL) seems to be the most common pediatric leukemia nowadays. It has a high curability rate of up to 90%, however drugs like glucocorticoids and chemotherapeutic agents that are used throughout the course of ALL treatment exert significant effects on demineralization and osteoclastogenesis. Therefore, osteoporosis is a frequent complication in patients with ALL. A paper published recently in the Journal of Pediatric Endocrinology and Metabolism discusses the beneficial effect of vitamin K2 (100 mcg menaquinone-7) and vitamin D3 (10 mcg calcitriol) on bone metabolism in children with ALL.
For the purpose of this cohort study, the researchers randomly enrolled 29 young patients (aged 1-17 years) that have recently been diagnosed with B precursor ALL (B-ALL). The study group received vitamin K2 and vitamin D3 with their chemotherapy, while the control group received chemotherapy only. After measuring serum levels of various markers and analyzing bone mineral density (BMD) parameters, the authors concluded that the results of this trial “[…] suggest an early beneficial effect of the combination of vitamin K2 and vitamin D3 on BMD in ALL patients especially during the period of intensive steroid therapy in the first months.”
“Major bone destruction may be induced by pediatric ALL treatment. This study shows that synergistic supplementation with vitamin K2 and D3 may provide protective effect for skeletal system of ALL patients and thus enhance the quality of their life,” says Dr. Katarzyna Maresz, president of the International Science and Health Foundation. “By addressing this problem, the authors increase awareness among pediatric hemato-oncologists and endocrinologists,” she adds.
Solmaz I, Ozdemir MA, Unal E, Abdurrezzak U, Muhtaroglu S, Karakukcu M. Effect of vitamin K2 and vitamin D3 on bone mineral density in children with acute lymphoblastic leukemia: a prospective cohort study. J Pediatr Endocrinol Metab. 2021 Feb 25;34(4):441-447. doi: 10.1515/jpem-2020-0637. PMID: 33639045.